Eng Huat Tan

TL;DR: Elotinib can prolong survival in patients with non-small-cell lung cancer after first-line or second-line chemotherapy, and five percent of patients discontinued erlot inib because of toxic effects.

TL;DR: Treatment with gefitinib was not associated with significant improvement in survival in either coprimary population, and there was pronounced heterogeneity in survival outcomes between groups of patients, with some evidence of benefit among never-smokers and patients of Asian origin.

TL;DR: In this paper, Afatinib is used for first-line treatment for epidermal growth factor receptor mutation-positive (EGFRm+) non-small-cell lung cancer (NSCLC) patients.

TL;DR: A CT-guided transthoracic needle biopsy of a right upper lobe pulmonary lesion was done on a 71-year-old man, who complained of severe abdominal distension followed by breathless ness immediately after the procedure, resulting in the current formation of post-procedural pneumothorax and pneumo–peritoneum.